Geode Capital Management LLC boosted its position in OncoSec Medical Inc (NASDAQ:ONCS) by 72.5% in the 4th quarter, Holdings Channel reports. The firm owned 388,688 shares of the biotechnology company’s stock after purchasing an additional 163,405 shares during the period. Geode Capital Management LLC’s holdings in OncoSec Medical were worth $248,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in ONCS. BlackRock Inc. grew its holdings in shares of OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 240,843 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 83,150 shares during the last quarter. Moloney Securities Asset Management LLC grew its holdings in shares of OncoSec Medical by 117.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 27,000 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 28,914 shares during the last quarter. 6.39% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:ONCS opened at $0.52 on Thursday. OncoSec Medical Inc has a 52 week low of $0.42 and a 52 week high of $1.96.
ONCS has been the topic of a number of recent analyst reports. Maxim Group reiterated a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a report on Monday, April 1st. Zacks Investment Research upgraded shares of OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. OncoSec Medical has an average rating of “Hold” and a consensus target price of $3.13.
ILLEGAL ACTIVITY WARNING: This article was first published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thestockobserver.com/2019/05/16/geode-capital-management-llc-has-248000-position-in-oncosec-medical-inc-oncs.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Read More: What is a blue-chip stock?
Want to see what other hedge funds are holding ONCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoSec Medical Inc (NASDAQ:ONCS).
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.